MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
89bio, Inc. (Nasdaq: ETNB)
Finance & Acquisitions: 89bio
Parents
89bio, Inc. (Nasdaq: ETNB)
Children
2019: Metabolic disease biotech 89bio files for a $70 million IPO
2025: Strategic Acquisition of 89bio by Roche Highlights Promising Growth in MASH and FGF21 Market
Jumps
Key People: 89bio
Organization & Developments: 89bio